KA/EN
Register
Medicines reference
Search
Search
Active substance

Oclacitinib

Favourites

Janus kinase (JAK) inhibitor. Registered in Georgia: 3 veterinary products. Forms: coated tablet.

Dose and use

Doses

Each dose comes with its source. Check the label of the product you use.

Active substance Oclacitinib
Dose calculatorCalculates the active-substance amount; it is not a prescription.
PatientSpecies and weight will be filled in automatically in other calculators.
Selected dose
Dose Species Indication Route Frequency Source
0.4–0.6 mg/kg Dog Allergic and Atopic Dermatitis (Pruritus) By mouth once daily
VMD SPC 2026
Official product label (SPC), VMD, UK
Approved by the UK Veterinary Medicines Directorate (VMD) as part of the product's authorisation. It applies to that product as authorised there.
Apoquel 3.6 mg, 5.4 mg and 16 mg film-coated tablets for dogs - Summary of Product Characteristics
UK Veterinary Medicines Directorate, 2026
0.4–0.6 mg/kg Dog Allergic and Atopic Dermatitis (Pruritus)
Loading
 By mouth every 12 hours for up to 14 days
VMD SPC 2026
Official product label (SPC), VMD, UK
Approved by the UK Veterinary Medicines Directorate (VMD) as part of the product's authorisation. It applies to that product as authorised there.
Apoquel 3.6 mg, 5.4 mg and 16 mg film-coated tablets for dogs - Summary of Product Characteristics
UK Veterinary Medicines Directorate, 2026
Before use

Safety information

Known Contraindications

  • Critical
    Do not use oclacitinib in dogs younger than 12 months or weighing less than 3 kg.
  • Critical
    Do not use oclacitinib in dogs with evidence of immune suppression, including hyperadrenocorticism, because it has not been evaluated in these patients.
  • Critical
    Do not use oclacitinib in dogs with evidence of immune suppression.
  • Critical
    Do not use oclacitinib in dogs with progressive malignant neoplasia. Lymphoma has been reported very rarely; papilloma and lipoma are more common.
  • Critical
    Known hypersensitivity to oclacitinib or any excipient, including lactose, is a contraindication.
  • Warning
    Oclacitinib may increase susceptibility to infection. Investigate and treat bacterial, fungal, and parasitic infection before treatment; pyoderma is very common.
  • Warning
    Oclacitinib is not recommended during pregnancy or in dogs intended for breeding.
  • Warning
    Oclacitinib is not recommended during lactation.
    Sources: Apoquel SPC
  • Caution
    Oclacitinib can increase susceptibility to infection and may worsen neoplastic disease. During prolonged treatment, monitor for infection and neoplasia and perform periodic complete blood counts and serum biochemistry. Do not use in dogs weighing less than 3 kg.
Latin name
Oclacitinib
Georgian name
ოკლაციტინიბი
Authorisation status
Authorised veterinary medicine
An authorised veterinary medicine containing this substance exists. Whether a particular use is on-label depends on the species and the indication - see each dose rule.
Registered in Georgia
3 of 3 forms
Products
Apoquel
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026
All forms and registration3

Registration in Georgia and abroad: the register, number, validity and source are behind (i).

Apoquel, Coated tablet

Oclacitinib 3.6 mg, film-coated tablet for dogs
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog
8.4/10
Very good
vetman assessment

Apoquel

Oclacitinib 3.6 mg, film-coated tablet for dogs
Assessed clinical scopeDog · Full labelled canine scope: control of pruritus associated with allergic dermatitis and treatment of clinical manifestations of atopic dermatitis · By mouth
Care settingVeterinary-directed outpatient dermatology treatment after investigation of underlying causes and infection
vetman score 8.4/10 Very good
Evidence confidence: High Georgia: Yes, veterinary · № 138-11 · Verified on 15 Oct 2026

A fast, strongly evidenced standard for the full labelled canine allergic and atopic dermatitis scope, provided causes and infections are managed and immunomodulatory risks are monitored.

Regulatory and scientific credibility9.5/10

All three exact strengths are covered by a current official SPC, central EU authorisation and active Georgian veterinary registration, with extensive trial and post-authorisation evidence.

Clinical efficacy9.0/10

Multiple randomised trials and specialist guidance show rapid, substantial control of allergic pruritus and atopic dermatitis; it controls manifestations but does not identify or remove the underlying trigger.

Safety and tolerability6.5/10

Most dogs tolerate labelled dosing, but immunomodulation can increase infection susceptibility and aggravate neoplastic disease; age, weight, immune suppression, progressive malignancy and reproductive restrictions are material, with periodic CBC and chemistry monitoring recommended long term.

Clinical practicality8.5/10

Oral dosing is straightforward and scored tablets support half-tablet selection; twice-daily induction for up to 14 days, daily maintenance, exact weight-band combinations and three-day storage of a split half require active prescribing discipline.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Do not use in dogs under 12 months, under 3 kg, with immune suppression such as hyperadrenocorticism, or with evidence of progressive malignant neoplasia.
  • Investigate and treat parasitic, bacterial and fungal causes or complications; monitor for infection and neoplasia during treatment.
  • For long-term maintenance, periodically monitor complete blood count and serum biochemistry and reassess individual benefit versus risk.
  • Not recommended during pregnancy, lactation or in breeding dogs; follow the exact weight-band table and use a divided half within three days.
Assessment sources
  1. VMD SPC 20262026
  2. EMA Apoquel EPAR2026
  3. Oclacitinib AD RCT2013
  4. ICADA 20152015
Assessed: 21 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Oclacitinib3.6 mg
Formulation Type
Coated tablet
Administration route
By mouth
Manufacturer
Zoetis · United States
Registration
Georgia Yes, veterinary
Veterinary (National Food Agency)
In the register: აპოქუელი 3.6მგ შემოგარსული ტაბლეტები ძაღლებისთვის
№ 138-11
Verified on: 15 Oct 2026
 EU Yes, veterinary
Verified on: 15 Oct 2026
 UK Yes, veterinary
Verified on: 15 Oct 2026
 US Yes, veterinary
№ NADA 141-345
Verified on: 15 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026

Apoquel, Coated tablet

Oclacitinib 5.4 mg, film-coated tablet for dogs
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog
8.4/10
Very good
vetman assessment

Apoquel

Oclacitinib 5.4 mg, film-coated tablet for dogs
Assessed clinical scopeDog · Full labelled canine scope: control of pruritus associated with allergic dermatitis and treatment of clinical manifestations of atopic dermatitis · By mouth
Care settingVeterinary-directed outpatient dermatology treatment after investigation of underlying causes and infection
vetman score 8.4/10 Very good
Evidence confidence: High Georgia: Yes, veterinary · № 139-11 · Verified on 15 Oct 2026

A fast, strongly evidenced standard for the full labelled canine allergic and atopic dermatitis scope, provided causes and infections are managed and immunomodulatory risks are monitored.

Regulatory and scientific credibility9.5/10

All three exact strengths are covered by a current official SPC, central EU authorisation and active Georgian veterinary registration, with extensive trial and post-authorisation evidence.

Clinical efficacy9.0/10

Multiple randomised trials and specialist guidance show rapid, substantial control of allergic pruritus and atopic dermatitis; it controls manifestations but does not identify or remove the underlying trigger.

Safety and tolerability6.5/10

Most dogs tolerate labelled dosing, but immunomodulation can increase infection susceptibility and aggravate neoplastic disease; age, weight, immune suppression, progressive malignancy and reproductive restrictions are material, with periodic CBC and chemistry monitoring recommended long term.

Clinical practicality8.5/10

Oral dosing is straightforward and scored tablets support half-tablet selection; twice-daily induction for up to 14 days, daily maintenance, exact weight-band combinations and three-day storage of a split half require active prescribing discipline.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Do not use in dogs under 12 months, under 3 kg, with immune suppression such as hyperadrenocorticism, or with evidence of progressive malignant neoplasia.
  • Investigate and treat parasitic, bacterial and fungal causes or complications; monitor for infection and neoplasia during treatment.
  • For long-term maintenance, periodically monitor complete blood count and serum biochemistry and reassess individual benefit versus risk.
  • Not recommended during pregnancy, lactation or in breeding dogs; follow the exact weight-band table and use a divided half within three days.
Assessment sources
  1. VMD SPC 20262026
  2. EMA Apoquel EPAR2026
  3. Oclacitinib AD RCT2013
  4. ICADA 20152015
Assessed: 21 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Oclacitinib5.4 mg
Formulation Type
Coated tablet
Administration route
By mouth
Manufacturer
Zoetis · United States
Registration
Georgia Yes, veterinary
Veterinary (National Food Agency)
In the register: აპოქუელი 5.4მგ შემოგარსული ტაბლეტები ძაღლებისთვის
№ 139-11
Verified on: 15 Oct 2026
 EU Yes, veterinary
Verified on: 15 Oct 2026
 UK Yes, veterinary
Verified on: 15 Oct 2026
 US Yes, veterinary
№ NADA 141-345
Verified on: 15 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026

Apoquel, Coated tablet

Oclacitinib 16 mg, film-coated tablet for dogs
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog
8.4/10
Very good
vetman assessment

Apoquel

Oclacitinib 16 mg, film-coated tablet for dogs
Assessed clinical scopeDog · Full labelled canine scope: control of pruritus associated with allergic dermatitis and treatment of clinical manifestations of atopic dermatitis · By mouth
Care settingVeterinary-directed outpatient dermatology treatment after investigation of underlying causes and infection
vetman score 8.4/10 Very good
Evidence confidence: High Georgia: Yes, veterinary · № 141-11 · Verified on 15 Oct 2026

A fast, strongly evidenced standard for the full labelled canine allergic and atopic dermatitis scope, provided causes and infections are managed and immunomodulatory risks are monitored.

Regulatory and scientific credibility9.5/10

All three exact strengths are covered by a current official SPC, central EU authorisation and active Georgian veterinary registration, with extensive trial and post-authorisation evidence.

Clinical efficacy9.0/10

Multiple randomised trials and specialist guidance show rapid, substantial control of allergic pruritus and atopic dermatitis; it controls manifestations but does not identify or remove the underlying trigger.

Safety and tolerability6.5/10

Most dogs tolerate labelled dosing, but immunomodulation can increase infection susceptibility and aggravate neoplastic disease; age, weight, immune suppression, progressive malignancy and reproductive restrictions are material, with periodic CBC and chemistry monitoring recommended long term.

Clinical practicality8.5/10

Oral dosing is straightforward and scored tablets support half-tablet selection; twice-daily induction for up to 14 days, daily maintenance, exact weight-band combinations and three-day storage of a split half require active prescribing discipline.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Do not use in dogs under 12 months, under 3 kg, with immune suppression such as hyperadrenocorticism, or with evidence of progressive malignant neoplasia.
  • Investigate and treat parasitic, bacterial and fungal causes or complications; monitor for infection and neoplasia during treatment.
  • For long-term maintenance, periodically monitor complete blood count and serum biochemistry and reassess individual benefit versus risk.
  • Not recommended during pregnancy, lactation or in breeding dogs; follow the exact weight-band table and use a divided half within three days.
Assessment sources
  1. VMD SPC 20262026
  2. EMA Apoquel EPAR2026
  3. Oclacitinib AD RCT2013
  4. ICADA 20152015
Assessed: 21 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Oclacitinib16 mg
Formulation Type
Coated tablet
Administration route
By mouth
Manufacturer
Zoetis · United States
Manufacturer (register)
Zoetis Inc., United States
Manufacturer and country as in the veterinary medicines register (National Food Agency), row 842, 19 Oct 2026.
Source: NFA veterinary medicines register ↗
Registration
Georgia Yes, veterinary
Veterinary (National Food Agency)
In the register: აპოქუელი 16მგ შემოგარსული ტაბლეტები ძაღლებისთვის
№ 141-11
Verified on: 15 Oct 2026
 EU Yes, veterinary
Verified on: 15 Oct 2026
 UK Yes, veterinary
Verified on: 15 Oct 2026
 US Yes, veterinary
№ NADA 141-345
Verified on: 15 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026

Professional reference for veterinary professionals. Not advertising and not a substitute for the product label/SPC.

For veterinary professionals only. It does not replace clinical judgement or the product label; check the dose in the official label (SPC). vetman is not liable for harm caused by using this information.

Trademarks belong to their owners; vetman is not affiliated with the manufacturers and receives no payment from them.

The database is protected under Chapter VII of the Law of Georgia on Copyright and Related Rights; automated or bulk copying is prohibited.

This reference is still growing. Missing a product? Let us know. · Report an error or request an addition · Updated: 16 Oct 2026

All of this shows in vetman as you prescribe

The dose for the patient's weight, registration in Georgia and controlled status, right on the prescription.

Register Demo ↗